Browsing by Author Antoniello, D

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue DateViews
 
A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Gane, ESevinsky, HYuen, RMFAnderson, MCloherty, GThi, EPWattamwar, TSofia, MJGray, KAntoniello, DEley, TPicchio, GSims, K
2021
9
 
Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729. Poster Presentation (SAT 448)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFStrasser, SSukeepaisarnjaroen, WSharma, VAntoniello, DMedvedeva, EThi, EPPicchio, GEley, TSims, K
2022
 
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients. Poster Presentation (SAT396)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Ganchua, SParatala, BIott, CYuen, RMFGane, EJEley, TSims, KGray, KAntoniello, DLam, AMSofia, MJPicchio, GThi, EP
2022
 
Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers
Proceeding/Conference:Journal of Hepatology
Paratala, BPark, J-JGanchua, SCGane, EYuen, RMFLee, ACHMoore, CLam, AMSevinsky, HSims, KAntoniello, DSofia, MJPicchio, GThi, EP
2021
10
 
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WHolmes, JLeerapun, ATangkijvanich, PStrasser, SJucov, AGane, EJThi, EPSevinsky, NMedvedeva, ESharma, VGray, KAntoniello, DPicchio, GSims, KEley, T
2022
 
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells. Poster Presentation (SAT397)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Ganchua, SCParatala, BIott, CGane, EJYuen, RMFEley, TSims, KGray, KAntoniello, DLam, AMSofia, MJPicchio, GThi, EP
2022
 
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Proceeding/Conference:Journal of Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WStrasser, STangkijvanich, PHolmes, JLeerapun, AJucov, AThi, EPWattamwar, TSofia, MJSevinsky, HGray, KAntoniello, DEley, TPicchio, GSims, KGane, E
2021
14
Showing results 1 to 7 of 7